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Abstract 
Purpose: We investigate the use and impact of a vaginal brachytherapy boost (VBB) after pelvic radiotherapy for 
stage III endometrial adenocarcinoma on vaginal and pelvic control. 
Material and methods: One hundred patients treated from 1998-2011 with surgery and adjuvant therapy with or 
without a VBB were included. Variables examined were grade, stage, lymphovascular space invasion (LVSI), vaginal 
involvement (VI), cervical stromal involvement (CSI), myometrial invasion (MI), and a VBB. Failure was scored as 
vaginal, or pelvic. Fisher’s exact test assessed association between variables with vaginal and pelvic control. 
Results: With a median follow up of 43 months, 31% were stage IIIA, 6% stage IIIB, and 63% stage IIIC. Thirty-eight 
(38%) received pelvic radiotherapy alone, and 62% received adjuvant chemotherapy. Of the 100 patients, 82 were 
treated with a VBB, 10 were not treated with a VBB, and 8 were not treated with RT. Of the 82 patients who received 
a VBB, 5 failed in the vagina with vaginal and pelvic control rates of 94% and 92%. The impact of VB reached borderline 
significance with its impact on pelvic control, 92% vs. 70% (p = 0.056), and did not affect vaginal control, 94% and 90% 
(p = 0.50). Neither tumor grade, LVSI, CSI, stage, nor LVSI (p > 0.05) statistically significantly impacted vaginal control. 
Conclusions: There are no clinical guidelines for the use of a VBB in stage III endometrial cancer. The majority of 
our patients were treated with a VBB and experienced excellent pelvic and vaginal control. The presence of traditional 
adverse features did not negatively impact control in our patient cohort. However, the role of a VBB needs further 
investigation to understand the incremental benefit beyond pelvic RT. 
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Purpose 
Endometrial cancer is the most common female malig-
nancy of gynecologic origin with an estimated incidence 
of 47,130 new cases and 8,010 deaths in 2012 [1]. Unfor-
tunately, there has been little change in 5-year overall 
survival rates since the mid 1970’s. The management of 
endometrial cancer therefore continues to evolve with re-
finement of both surgical approaches and adjuvant thera-
py. Surgery remains the indisputable standard of care for 
initial management of uterine disease. Various approach-
es continue to be utilized for management of locally ad-
vanced endometrial cancer, especially for women with 
regional lymph node involvement. It has been well estab-
lished that women with FIGO stage III endometrial cancer 
benefit from adjuvant therapy in the form of chemother-
apy and radiotherapy to improve local control, disease 
free survival and overall survival outcomes [2-6]. Often 
a matter of institutional preference, these  modalities are 
used independently or in some sequential combination, 
as both have shown benefit albeit with continual debate 
surrounding ideal order and timing of these therapies [6]. 
An unanswered question is whether women with 
stage III disease who receive whole pelvis radiation 
therapy (WPRT) as part of their adjuvant therapy de-
rive meaningful benefit from the addition of a vaginal 
brachytherapy boost (VBB). Currently, there is limited 
data addressing the need for vaginal brachytherapy as 
a compliment to pelvic radiotherapy or systemic che-
motherapy in stage III endometrial cancer patients. This 
investigation examines the impact of a VBB on disease 
control, using patients treated with adjuvant WPRT with 
or without vaginal brachytherapy following optimal sur-
gery for International Federation of Obstetrics and Gy-
necology (FIGO) stage III endometrial cancer. Currently, 
there are no guidelines for clinicians on when to consider 
a VBB. Our primary study endpoints include the impact 
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of a VBB on pelvic and vaginal control. We also explore 
the risk factors associated with the selection of a VBB. 
Material and methods 
The institutional tumor registry and departmental da-
tabases were queried to identify patients who were consec-
utively and definitively treated for FIGO stage III endome-
trial adenocarcinoma, clear cell or serous cancer between 
1998 and 2012. The Institutional Review Board granted 
permission for this study. Patient characteristics consid-
ered included age, race, Karnofsky performance status, 
ethnicity, and medical comorbidities including the pres-
ence of diabetes and hypertension. The pathological tumor 
characteristics included FIGO stage, degree of myometrial 
invasion, cervical stromal involvement, lymphovascular 
space invasion, grade, adnexal and vaginal involvement, 
and status of pelvic and paraaortic lymph nodes. Treat-
ment characteristics included type and number of che-
motherapy cycles given, external beam dose, treatment 
modality, and vaginal brachytherapy dose. Outcome mea-
sures were local control, vaginal, and pelvic control. 
A total of 100 consecutive patients were treated from 
1998 to 2012 were included in the analysis. All patients 
underwent a total abdominal, laproscopic, or robotic as-
sisted hysterectomy, and bilateral salpingo-oophorecto-
my with either lymphadenectomy or lymph node sam-
pling, peritoneal washings and omental biopsy. Patients 
had their pathology reviewed by a specialist in the field 
of gynecological cancer. One patient was treated preoper-
atively and was subsequently lost to follow-up. Descrip-
tive analyses were performed to characterize the clinical, 
demographic, and pathological features of the patient 
population. Assessed variables include performance sta-
tus, tumor grade, pathologic T stage, N stage, lympho-
vascular space invasion (LVSI), vaginal involvement (VI), 
lower uterine segment invasion (LUS), cervical stromal 
involvement (CSI), myometrial invasion (MI), and use of 
a VBB. Failure was scored as vaginal, pelvic, abdominal 
or distant. Fisher’s exact tests were used to assess the as-
sociation between these variables on vaginal and pelvic 
control. 
Results 
Patient characteristics 
As shown in Table 1, of the 100 patients, 13% were 
Latino, 43% white, and 8% black. Also 69% had a Karn-
ofsky performance status of 90 or 100. In terms of med-
ical comorbidity, 48% has diabetes and 52% had hyper-
tension. Table 2 presents the tumor characteristics of the 
patients. The stages of the patients were 31 stage IIIA, 
6 stage IIIB, 39 stage IIIC1, and 24 stage IIIC2. In addition, 
77% of the population was adenocarcinoma and 57% had 
LVSI, 30% had adenexal involvement, 43% had LUS in-
volvement, 31% CSI, and 8% had VI as shown in Table 2. 
Treatment 
Of the 100 patients, 82 were treated with WPRT and 
a VBB, 10 were treated with WPRT alone (no VBB), and 
8 were not treated with RT. In the analysis, 92 patients 
were treated with whole pelvic radiation for a total dose 
of 45-50.4 Gy in 1.8-2 Gy per fraction. A single patient was 
treated with whole abdominal radiotherapy to a dose of 
30 Gy followed by a boost of 19.8 Gy to the pelvis alone. 
The average elapsed time for the external beam was 
39 days. Three dimensional conformal radiation therapy 
was the primary method of external beam radiotherapy 
with the use of intensity modulated radiation therapy in-
creasing over the course of the study period. Sixty-two 
percent of patients were also treated with systemic che-
motherapy, the majority with carboplatin and paclitaxel 
for an average of 5 cycles, while cisplatin as a single agent 
was used in 3 patients. 
Among all patients, 82 patients were treated with 
a VBB using a high dose rate Ir-192 afterloader. Brachy-
therapy was delivered to the upper one-third to one-half 
of the vagina and was prescribed to either the surface 
Table 1. Patient characteristics 
Patients (n) 100
Ethnicity
Hispanic or Latino 13 
Not Hispanic or Latino 70 
Unknown/Not reported 17 
Race
American Indian/Alaska Native 0
Asian 6
Native Hawaiian or other Pacific Islander 3
Black or African American 8
White 43
More than one race 0
Unknown/Not reported 40
Performance Status
50 1
60 3
70 10
80 14
90 52
100 17
Diabetes
Yes 48
No 52
Hypertension
Yes 52
No 48
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or to 0.5 cm. Starting in 2009, all patients treated with 
brachytherapy had image simulation. This verification 
was a quality control measure to account for accuracy of 
the measured distended vaginal length and proper appli-
cator placement within the pelvis as shown in Figure 1. 
Most patients received 12-15 Gy in 3 fractions over the 
course of 7-14 days. 
Outcomes 
The median follow up time was 43 months. Among 
the 100 patients available for disease related outcome 
analysis, 94 patients experienced vaginal control. There 
was no statistically significant association between vagi-
nal control and a brachytherapy boost (p = 0.51). Of those 
treated with a brachytherapy boost, 82 patients (94%) 
experienced vaginal control. Of those who failed in the 
vagina, 5 of 6 were treated with a VBB. There were no sta-
tistically significant differences in vaginal control when 
examining pathologic variables such as grade, LVSI, CSI, 
MI, or LUS involvement in the population as shown in 
Table 3. In 8 patients who had VI, one experienced vagi-
nal failure. There was no statistical difference in rates of 
vaginal control based on vaginal involvement (p = 0.40). 
Table 2. Tumor characteristics 
Tumor characteristics Patient number
Patient pathologic stage (FIGO)
IIIA 31
IIIB 6
IIIC1 39
IIIC2 24
Patient pathologic T stage (AJCC)
T1a 16
T1b 27
T2 9
T3a 35
T3b 13
Patient pathologic N stage
N0 38
N1 37
N2 25
Patient pathologic M stage
0 99
1 1
Tumor histology
Adenocarcinoma 77
Carcinosarcoma 8
Clear cell carcinoma 4
Papillary serous carcinoma 11
Lymphovascular space invasion
Yes 57
No 41
Location of positive nodes
Pelvic 40
Paraaortic 20
Tumor characteristics Patient number
Adnexal involvement
Yes 30
No 69
Parametria involvement
Yes 15
No 85
Vaginal involvement
Yes 8
No 92
Positive pelvic wash
Yes 12
No 87
Tumor grade
1 28
2 26
3 0
Lower uterine involvement
Yes 43
No 57
Cervical stroma involvement
Yes 31
No 69
Cervical gland involvement
Yes 35
No 64
Patient’s margin status
Negative 92
Close (< 5 mm) 2
Positive 5
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Ten percent of patients failed in the pelvis as defined by 
failure in the pelvis and/or vagina, 7 of which were treat-
ed with a vaginal brachytherapy boost. For patients who 
experienced pelvic control, 93% were treated with a VBB. 
There was a trend for increasing pelvic control with the 
use of a boost, p = 0.056. There was no statistically signifi-
cant increase in pelvic failure based on LVSI, lymph node 
status, CSI, VI, or LUS involvement as shown in Table 3. 
During the follow up period, 11% recurred with distant 
metastatic disease, 15% in the para-aortic or pelvic lymph 
nodes, 13% failed in the abdomen. 
Discussion 
Adjuvant therapy for locally advanced endometrial 
cancer continues to evolve. Our study seeks to under-
stand the utility of a VBB, review the existing literature 
on stage 3 endometrial cancer outcomes, and explore the 
potential benefit of a VBB on vaginal and pelvic control. 
There is paucity in the literature regarding the addition 
of a VBB to whole pelvic radiation in this group of pa-
tients, and who may benefit from this additional therapy 
to whole pelvic radiation. 
For patients with stage III endometrial cancer, the 
attention to pelvic control is relevant. With the publica-
tion of GOG 122 in 1995, adjuvant systemic chemother-
apy was, in many regards, considered the new standard 
of care after demonstrating an overall survival benefit 
of systemic therapy over whole abdominal radiation at 
5 years [7]. However, in the systemic therapy group, the 
risk of relapse in the pelvis neared 20% [7]. Furthermore, 
several single institution studies have shown increased 
rates of pelvic relapse much higher than was demonstrat-
ed in GOG 122 [7-10]. In fact, Mundt et al. showed a pelvic 
recurrence rate of 47% in high risk pathologic endometri-
al adenocarcinoma treated with adjuvant chemotherapy 
and no radiation therapy. In addition, Klopp et al. pub-
lished their single institutional data confirming a high 
rate of pelvic failure in those receiving chemotherapy 
alone [8]. In this series, five-year pelvic-relapse-free sur-
vival (98% vs. 61%, p = 0.001), DSS (78% vs. 39%, p = 0.01), 
and overall survival (73% vs. 40%, p = 0.03) were signifi-
cantly better for the regional RT group than the system-
ic therapy group [8]. Another study by Secord et al. re-
viewed 256 patients with stage IIIC endometrial cancer 
[6]. The three-year RFS was 56% for chemotherapy alone, 
compared to 73% for radiation alone, and 73% for combi-
nation therapy (p = 0.12). Those receiving chemotherapy 
alone had the worst 3-year OS (78%) compared to either 
radiotherapy alone (95%), or combination therapy (90%) 
(p = 0.005) [6]. They conclude that radiation alone or che-
motherapy and radiation was associated with improved 
outcomes for patients with optimally resected stage IIIC 
adenocarcinoma compared to those treated with chemo-
therapy only [6]. Therefore, the risk of vaginal and pelvic 
control remains an issue in patients treated with chemo-
therapy alone, arguing for a role of consolidative radia-
tion therapy. 
Our study is one of the largest in the literature to re-
view stage III endometrial cancer related outcomes, and 
the only institutional data specifically investigating the 
role of a brachytherapy boost in this population. The role 
of a VBB remains controversial with wide differences in 
practice pattern variation. In a recent SEER analysis of 
stage IIIC endometrial adenocarcinoma, 51% were treat-
ed with adjuvant pelvic radiation and 21% were given 
a brachytherapy boost [11]. Even in the ongoing coopera-
tive group trials, such as the current GOG 258, which ran-
domizes stage III patients to chemotherapy alone versus 
chemoradiation followed by systemic therapy, the addi-
tion of vaginal brachytherapy is at the discretion of the 
treating physician. Depending on the instution of treat-
ment, patients are often offered a vaginal brachytherapy 
boost in the setting of LVSI, high grade disease, VI, or 
CSI. There also remains debate on the amount of vagina 
to include in the brachytherapy boost field. The majority 
of our patients were treated to the upper half of the vagi-
na, based on a vaginal measurement that was performed 
in the clinic prior to brachytherapy. 
One of the major factors in the decision to give a VBB 
is the potential risk of additional complications. As re-
Table 3. Pathological characteristic variables on pe-
lvic and vaginal control using the Fisher’s exact test 
for significance 
Pathologic characteristic Pelvic control
p-value
Vaginal control
p-value
VBB 0.056 0.508
LVSI 0.462 1
Cervical Involvement 0.495 0.370
Grade 0.691 0.759
Lymph node status 0.915 0.764
Vaginal involvement 0.583 0.401
Lower uterine segment 0.741 0.397
VBB – vaginal brachytherapy boost, LVSI – lymphovascular space invasion 
Fig. 1. Image verification of a vaginal brachytherapy im-
plantation 
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ported in the literature, there is an acceptable rate of re-
ported toxicity with the addition of a VBB. Klopp et al. 
described the major complications in stage 3 endome-
trial cancer after pelvic radiation with 86% of patients 
receiving a VBB [8]. There was one grade 4 small bowel 
obstruction in a patient treated with external beam RT, 
for an overall radiation-related major complication rate 
of 2% [8]. Rates of minor complications were not recorded 
[8]. In the RTOG trial 97-08, 22% of endometrial cancer 
patients had stage IIIC [12]. The treatment for the 46 pa-
tients on trial was surgery followed by adjuvant concur-
rent chemoradiotherapy. Patients received whole pelvis 
RT to 45 Gy followed by a VBB, with cisplatin (50 mg/m2) 
administered on days 1 and 28, followed by four courses 
of cisplatin (50 mg/m2) and paclitaxel (175 mg/m2) [12]. 
At 4 years, the reported late toxicity for this regimen was 
grade 1 in 16%, grade 2 in 41%, grade 3 in 16%, and grade 4 
in 5% [12]. 
In our study, there was a trend for increased pel-
vic control in those who had VI and were boosted with 
brachytherapy. Eighty-two of the one hundred patients in 
the study were treated with a VBB to achieve a vaginal 
control rate of 94% and pelvic control rate of 90%. This 
control rate is impressive given that 57% had LVSI, 30% 
had adenexal involvement, 43% had LUS involvement, 
31% CSI, and 8% had VI. In addition, the vast majority of 
our patients had lymph node involvement. In the SEER 
analysis, the addition of a radiation therapy improved 
survival in those with stage IIIC endometrial cancer with 
direct tumor extenstion with a 5 year overall survival rate 
of 34%, 47%, and 63% in those receiving adjuvant che-
motherapy alone, external beam radiation, and a vaginal 
brachytherapy boost [11]. Furthermore, when direct ex-
tension of the primary tumor was present, the addition 
of brachytherapy conferred a greater survival advantage 
[11]. In our population, there was a trend for improved 
vaginal control in those who had vaginal involvement, but 
there was no effect of the VBB in respect to margin status. 
Furthermore, our study population experienced a high 
vaginal control rate, 94%, and pelvic control, 90% with 
the majority of patients treated with trimodality therapy: 
chemotherapy, consolidative pelvic radiation, and a VBB. 
The ongoing question in the field is the questionable 
incremental benefit of additional radiation to the vaginal 
apex. Is the addition of vaginal brachytherapy clinically 
significant for reducing apex recurrences? Should it be 
given to all patients with stage III endometrial adenocar-
cinoma? Unfortunately, our data is not able to definitive-
ly answer this question. A limitation of our study is that 
a high number of patients were treated with a brachyther-
apy boost, reflecting the decision of the physician to de-
liver a boost in the majority of cases. Therefore, our pa-
per is intended to be thought provoking on the selection 
and role of a vaginal brachytherapy boost in this defined 
patient population. Our study reports a low percentage 
of locoregional failure. Therefore, we are unable to illus-
trate risk factors that could potentially predict for vaginal 
failure, and thus warrant the use of a VBB. Perhaps the 
combination of systemic therapy and radiation therapy 
are altering the patterns of failure, and the vaginal con-
trol would be sufficient without the additional therapy. 
In terms of patterns of failure, a phase III trial of adju-
vant chemotherapy versus pelvic radiotherapy was con-
ducted by Maggi et al. After a median follow-up was 95.5 
months, it failed to replicate the results of GOG 122 and 
revealed no statistical difference in overall survival or 
progression free survival. The chemotherapy arm trend-
ed towards delayed metastatic disease and the radiother-
apy arm trended towards improved local control, but nei-
ther achieved statistical significance. However, this trial 
did not report use of vaginal brachytherapy. Compared 
to single institutional data and the results of GOG 122, 
our patients had improved vaginal and pelvic control 
consistent with a recently published retrospective review 
from Brigham and Women’s Hospital, which examined 
the outcomes of patients treated with adjuvant therapy 
for FIGO IIIC endometrial adenocarcinoma [3,4,6,7,9,10]. 
Conclusions 
There is no consensus on the addition of a VBB in 
stage 3 endometrial carcinoma. The majority of our pa-
tients with stage III endometrial cancer were treated with 
a VBB, and experienced excellent pelvic and vaginal con-
trol. There was no difference between pelvic or vaginal 
control with the addition of a VBB. However, the pres-
ence of high grade, VI, LVSI, CSI did not adversely affect 
outcomes in our patient cohort, suggesting that the role of 
a VBB in this population needs further exploration. 
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